3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
Conditions
Pancreatic Neoplasms
36
Colorectal Neoplasms
17
Small Cell Lung Carcinoma
8
Neoplasms
8
Stomach Neoplasms
7
Neoplasm Metastasis
5
Sarcoma, Ewing
4
Rhabdomyosarcoma
4
Recurrence
4
Osteosarcoma
4
Cholangiocarcinoma
4
Biliary Tract Neoplasms
4
Rectal Neoplasms
3
Ovarian Neoplasms
3
Triple Negative Breast Neoplasms
2
Solid Tumor
2
Neuroblastoma
2
Nasopharyngeal Carcinoma
2
Metastatic Pancreatic Adenocarcinoma
2
Head and Neck Neoplasms
2
Glioma
2
Glioblastoma
2
Gastrointestinal Neoplasms
2
Fallopian Tube Neoplasms
2
Esophageal Neoplasms
2
Wilms Tumor
1
Weight Loss
1
Somatostatinoma
1
Solid Tumor Cancer
1
Small Cell Lung Cancer Extensive Stage
1
Interventions
Cisplatin
12
Everolimus
10
Nivolumab
8
Etoposide
8
Temozolomide
6
Carboplatin
6
atezolizumab
5
Irinotecan
5
Ipilimumab
5
Fluorouracil
5
Bevacizumab
5
pembrolizumab
4
lutetium Lu 177 dotatate
4
Capecitabine
4
avelumab
3
Paclitaxel
3
IFL protocol
3
surufatinib
2
sintilimab
2
dostarlimab
2
cabozantinib
2
belinostat
2
azaspirane
2
Topotecan
2
Radiosurgery
2
Positron Emission Tomography Computed Tomography
2
PE regimen
2
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
2
Magnetic Resonance Imaging
2
Leucovorin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Carcinoma, Neuroendocrine
×
irinotecan sucrosofate
×
Clear all
NCT03837977
2024-12-30
NET02
The Christie NHS Foundation Trust
Phase 2
Completed
58 enrolled